CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy

International Journal of Dermatology

Volumn 50, Issue 8, 2011, Pages 948-955

  Yildirim, Fatma Elif ^a   Karaduman, Ayşen ^a   Pinar, Asli ^a   Aksoy, Yasemin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BIOLOGICAL MARKER; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV; ETANERCEPT; METHOTREXATE; PSORALEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS SEVERITY INDEX; PUVA; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ADENOSINE DEAMINASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYCLOSPORINE; DIPEPTIDYL PEPTIDASE 4; FEMALE; FICUSIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; ULTRAVIOLET THERAPY; YOUNG ADULT;

EID: 79960634133     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04799.x     Document Type: Article

References (37)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
2. Lee MR, Cooper J. Immunopathogenesis of psoriasis. Aust J Dermatol 2006; 47: 151-159.
3. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82: 53-73.
4. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-264.
5. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP-IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.
6. da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002; 168: 4462-4471.
7. Jullien D, Prinz JC, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with Efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208: 297-306.
8. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and activated) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997; 186: 1865-1872.
9. Shaker OG, Moustafa W, Essmat S, et al. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem 2006; 39: 119-125.
10. Tritsch GL, Minowada J. Differences in purine metabolizing enzyme activities in human leukemia T-cell, B-cell and null cell lines. J Natl Cancer Inst 1978; 60: 1301-1304.
11. Dong RP, Kameoka J, Hegen M, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996; 156: 1349-1355.
12. Adams A, Harkness RA. Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol 1976; 26: 647-649.
13. Bükülmez G, Akan T, Ciliv G. Serum adenosine deaminase levels in patients with psoriasis: a prospective case-control study. Eur J Dermatol 2000; 10: 274-276.
14. Erbaǧci Z, Erbagci AB, Koyluoglu O, Tuncel AA. Serum adenosine deaminase activity in monitoring disease activity and response to therapy in severe psoriasis. Acta Medica (Hradec Kralove) 2006; 49: 101-104.
15. van Lingen RG, van de Kerkhof PC, de Jong EM, et al. Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients. Exp Dermatol 2008; 17: 343-348.
16. van Lingen RG, van de Kerkhof PC, Seyger MM, et al. CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008; 158: 1264-1272.
17. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
18. Giusti G, Galanti B. Colorimetric method. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Weinheim: Verlag Chemie, 1984: 315-323.
19. Nagatsu T, Hino M, Fuyamada H, et al. New chromogenic substrates for X-Pro dipeptidyl aminopeptidase. Anal Biochem 1976; 74: 466-476.
20. Koizumi H, iizuka H, Aoyagi T, Miura Y. Adenosine deaminase in human epidermis from healthy and psoriatic subjects. Arch Dermatol Res 1983; 275: 340-344.
21. Köse K, Utas S, Yazici C, et al. Effect of propylthiouracil on adenosine deaminase activity and thyroid function in patients with psoriasis. Br J Dermatol 2001; 144: 1121-1126.
22. Tikhonov Yu V, Markusheva L, Toguzov RT. Metabolism of purine compounds in psoriasis. Klin Lab Diagn 1998; 3: 3-6.
23. Koizumi H, Ohkawara A. Adenosine deaminase activity in sera of patients with psoriasis, mycosis fungoides and adult T cell leukemia. Acta Derm Venereol 1992; 72: 410-412.
24. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64: 65-68.
25. Hildebrandt M, Rose M, Ruter J, et al. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 2001; 36: 1067-1072.
26. Kullertz G, Boigk J. Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis. Z Rheumatol 1986; 45: 52-56.
27. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001; 21: 69-74.
28. Scholzova E, Sedova L, Mares V, et al. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) - the novel players in pathogenesis of rheumatoid and psoriatic arthritides. Eur J Biochem 2004; 271: 104-105.
29. Novelli M, Savoia P, Fierro MT, et al. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol 1996; 134: 1052-1056.
30. Savoia P, Novelli M, De Matteis A, et al. Effects of topical calcipotriol on the expression of adhesion molecules in psoriasis. J Cutan Pathol 1998; 25: 89-94.
31. Bock O, Kreiselmeyer I, Mrowietz U. Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis. Exp Dermatol 2001; 10: 414-419.
32. Elgun S, Keskinege A, Kumbasar H. Dipeptidyl peptidase IV and adenosine deaminase activity. Decrease in depression. Psychoneuroendocrinology 1999; 24: 823-832.
33. Bauvois B, Sancéau J, Wietzerbin J. Human U937 cell surface peptidase activities: characterization and degradative effect on tumor necrosis factor-alpha. Eur J Immunol 1992; 22: 923-930.
34. Salgado FJ, Vela E, Martín M, et al. Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine 2000; 12: 1136-1141.
35. van Lingen RG, van Erp PE, Seyger MM, et al. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement. Acta Derm Venereol 2009; 89: 518-520.
36. Bonnekoh B, Pommer AJ, Böckelmann R, et al. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment. Skin Pharmacol Physiol 2007; 20: 237-252.
37. Thielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol 2007; 127: 1042-1051.